TNFSF10 and cancer: A notable example of TRAIL-resistant cancer is HT1080, where on average, only 40% of cells respond to treatment.9,10 In a previous work, we developed an ordinary differential equation-based kinetic model to track the cell survival and apoptosis signaling, through MAP kinases/NF-κB and caspase -8/-3 dynamics, respectively, in TRAIL-stimulated HT1080.10 To sensitize HT1080 to TRAIL treatment, we performed several in silico intracellular target suppression, and evaluated the overall cell survival ratios.